[{"address1": "9704 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 251 5172", "fax": "301 251 5321", "website": "https://www.macrogenics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 \u00d7 CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00d7 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 339, "companyOfficers": [{"maxAge": 1, "name": "Dr. Scott  Koenig M.D., Ph.D.", "age": 71, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 1199494, "exercisedValue": 0, "unexercisedValue": 459000}, {"maxAge": 1, "name": "Mr. James  Karrels", "age": 56, "title": "Senior VP, CFO & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 693306, "exercisedValue": 0, "unexercisedValue": 162000}, {"maxAge": 1, "name": "Dr. Stephen L. Eck M.D., Ph.D.", "age": 68, "title": "Senior VP of Clinical Development & Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 766848, "exercisedValue": 0, "unexercisedValue": 180000}, {"maxAge": 1, "name": "Mr. Eric Blasius Risser", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 651362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas M. Spitznagel Ph.D.", "age": 56, "title": "Senior Vice President of Technical Operations", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 550974, "exercisedValue": 204497, "unexercisedValue": 490417}, {"maxAge": 1, "name": "Dr. Ezio  Bonvini M.D.", "age": 69, "title": "Senior VP of Research & Chief Scientific Officer", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 612208, "exercisedValue": 264031, "unexercisedValue": 199063}, {"maxAge": 1, "name": "Mr. Jeffrey Stuart Peters", "age": 52, "title": "Senior VP, General Counsel & Corporate Compliance Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lynn  Cilinski", "age": 65, "title": "VP, Controller & Treasurer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.63, "open": 4.63, "dayLow": 4.49, "dayHigh": 4.8483, "regularMarketPreviousClose": 4.63, "regularMarketOpen": 4.63, "regularMarketDayLow": 4.49, "regularMarketDayHigh": 4.8483, "beta": 2.081, "forwardPE": -2.0776255, "volume": 1709049, "regularMarketVolume": 1709049, "averageVolume": 2588638, "averageVolume10days": 4595740, "averageDailyVolume10Day": 4595740, "marketCap": 284982432, "fiftyTwoWeekLow": 3.14, "fiftyTwoWeekHigh": 21.88, "priceToSalesTrailing12Months": 6.572928, "fiftyDayAverage": 13.2529, "twoHundredDayAverage": 10.248225, "currency": "USD", "enterpriseValue": 134757248, "profitMargins": -0.53599, "floatShares": 54772334, "sharesOutstanding": 62633500, "sharesShort": 9964359, "sharesShortPriorMonth": 6446695, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.1593, "heldPercentInsiders": 0.02646, "heldPercentInstitutions": 1.12282, "shortRatio": 7.47, "shortPercentOfFloat": 0.19559999, "impliedSharesOutstanding": 63734700, "bookValue": 1.697, "priceToBook": 2.6812022, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -23239000, "trailingEps": -0.38, "forwardEps": -2.19, "pegRatio": 0.01, "enterpriseToRevenue": 3.108, "enterpriseToEbitda": -0.77, "52WeekChange": -0.02569592, "SandP52WeekChange": 0.26137078, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MGNX", "underlyingSymbol": "MGNX", "shortName": "MacroGenics, Inc.", "longName": "MacroGenics, Inc.", "firstTradeDateEpochUtc": 1381411800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "322da638-92af-3f5e-9fb0-7915224804a7", "messageBoardId": "finmb_600911", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.55, "targetHighPrice": 18.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.8, "targetMedianPrice": 8.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 184236992, "totalCashPerShare": 2.942, "ebitda": -175064992, "totalDebt": 34012000, "quickRatio": 3.433, "currentRatio": 3.633, "totalRevenue": 43357000, "debtToEquity": 32.04, "revenuePerShare": 0.699, "returnOnAssets": -0.38774, "returnOnEquity": -0.21575001, "freeCashflow": -51757876, "operatingCashflow": -111015000, "revenueGrowth": -0.628, "operatingMargins": -5.9040003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-27"}]